Topic: autism spectrum disorders
Finch thinks it has a shot at winning FDA approval of the full-spectrum microbiota drug if the ongoing clinical study generates “compelling results.”
Akili Interactive is teaming up with Osaka-based Shionogi to help bring the first prescription digital therapeutics to Japan and Taiwan.
Axial Biotherapeutics raised $25 million to fund programs aimed at the gut microbiome, to treat Parkinson’s disease and autism spectrum disorder.
NeuroPointDX has launched what it says is the first objective blood test set up to help diagnose children with autism spectrum disorder earlier.
EIP Pharma is enrolling a phase 2b trial of neflamapimod, which targets synaptic dysfunction.
Instead of seeking the underlying cause of a group of symptoms, scientists started with a mutation and then tracked down people who have it.
Roche has been awarded breakthrough status for a drug that has shown some signs of activity in autism spectrum disorders, according to reports.
The co-founders of autoimmune biotech Receptos are back with BlackThorn, a startup that aims to succeed in treacherous neuro territory by using physiological measures, rather than just a qualitative clinician assessment, to better define the diseases and their populations.
Axial is working to treat CNS disorders in a new way—one that doesn’t involve the blood-brain barrier. Instead, the biotech has a three-pronged approach to treat disease through the gut-brain connection.
A new target for the treatment of MeCP2 duplication syndrome could be useful in treating autism and other neurological conditions.